Recent developments in cancer treatment highlight promising advances in immunotherapy and repurposed drugs. A Phase 1 clinical trial involving an injection directly into tumors showed that six out of 12 patients experienced tumor shrinkage, with two achieving complete remission and no serious side effects reported. Rockefeller University researchers have been investigating CD40 agonist antibodies, a class of immunotherapy drugs that activate the immune system, showing mixed results over two decades. In Russia, human trials have begun for a novel skin cancer vaccine designed to train the immune system to identify and eliminate malignant cells within approximately a week. Additionally, ivermectin, an FDA-approved drug, is gaining attention for its potential anti-cancer properties, particularly due to its effect on the gut microbiome by increasing bifidobacteria. Renowned oncologists, including Dr. Angus Dalgleish, are exploring ivermectin as a next-generation cancer therapy. Patient testimonials have reported remarkable responses, such as a 44-year-old man from Texas with Stage 4 lung cancer achieving no evidence of disease after four months of treatment involving ivermectin, mebendazole, and fenbendazole, and a 64-year-old man from Armenia with Stage 4 rectal cancer and liver metastases showing significant improvement after three weeks. Furthermore, studies suggest that experimental off-the-shelf cancer vaccines are already prolonging lives, marking a potential shift in cancer treatment paradigms.